This grant from the National Heart, Lung, and Blood Institute aims to support research addressing scientific questions to accelerate the use of stem cell-derived blood products as therapeutics. While progress has been made in producing red blood cells and platelets using cellular engineering methods, fundamental questions related to cell differentiation and maturation need to be addressed for efficient production. The grant also highlights companion FOAs supporting small business research for developing enhanced techniques and tools to produce clinically-useful stem cell-derived blood products. Closing date for applications is Feb 20, 2015.
Opportunity ID: 269428
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HL-15-022 |
| Funding Opportunity Title: | Stem Cell-Derived Blood Products for Therapeutic Use (R01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | 8 |
| Assistance Listings: | 93.839 — Blood Diseases and Resources Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 07, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Feb 20, 2015 |
| Current Closing Date for Applications: | Feb 20, 2015 |
| Archive Date: | Mar 23, 2015 |
| Estimated Total Program Funding: | $3,600,000 |
| Award Ceiling: | $300,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments City or township governments County governments For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities State governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Stem cell technology holds the promise of providing a nearly limitless source of safe, immune-matched cells for clinical use. One of the first areas where this promise can be realized is through cell products that lack a nucleus and thus face fewer regulatory hurdles, such as red blood cells and platelets. Considerable progress has been made but scientific questions remain and improved tools to enhance the production are required if translation to clinical use is to be achieved. To this end, this FOA will support research addressing remaining scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. While production of sufficient numbers of cells such as platelets and red cells has been demonstrated using cellular engineering methods, basic research questions related to cell differentiation and maturation remain, which if elucidated, may allow for the development of new ways to efficiently produce clinically-useful stem cell-derived platelets or red blood cells. In addition to this FOA, two companion FOAs (RFA-HL-15-029 and RFA-HL-15-030) will support small business research to develop improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-022.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-C | FORMS-C | PKG00209704 | Jan 20, 2015 | Feb 20, 2015 | View |
Package 1
Mandatory forms
269428 RR_SF424_2_0-2.0.pdf
269428 PHS398_ResearchPlan_2_0-2.0.pdf
269428 PHS398_CoverPageSupplement_2_0-2.0.pdf
269428 RR_KeyPersonExpanded_2_0-2.0.pdf
269428 RR_OtherProjectInfo_1_3-1.3.pdf
269428 PerformanceSite_2_0-2.0.pdf
Optional forms
269428 RR_SubawardBudget30_1_3-1.3.pdf
269428 PlannedReport-1.0.pdf
269428 PHS398_CumulativeInclusionReport-1.0.pdf
269428 PHS398_ModularBudget_1_2-1.2.pdf
269428 RR_Budget_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
